<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[AsiaBioBridge]]></title><description><![CDATA[Asiabiobridge]]></description><link>https://www.asiabiobridge.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Sun, 20 Sep 2026 15:52:28 GMT</lastBuildDate><atom:link href="https://www.asiabiobridge.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[China's Pharma Plan to 2030 Runs at Two Speeds: What It Means for Europe and for Chinese Innovators]]></title><description><![CDATA[On 18 September, Beijing published its industrial blueprint for pharmaceuticals and medical devices. Read against the results of the previous plan, it tells European companies and Chinese innovators two different but complementary things.]]></description><link>https://www.asiabiobridge.com/post/chinas-pharma-plan-to-2030-runs-at-two-speeds-what-it-means-for-europe-and-for-chinese-innovators</link><guid isPermaLink="false">e351593d-f338-4e1d-9b5d-9bb2658d932a</guid><pubDate>Sun, 20 Sep 2026 11:20:41 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/919ca1_1d038bdaf443421c963c4635c49bcf88~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>AsiaBioBridge</dc:creator></item></channel></rss>